Why the Elyra launch matters for Becton Dickinson (BDX) shareholders

Becton Dickinson (BDX) has introduced its Elyra Thulium Fiber Laser System for kidney stone care, rounding out its urologic portfolio and drawing fresh attention to how this product expansion might influence the stock.

At a share price of US$147.12, Becton Dickinson has seen its share price fall over the past quarter and year to date, while the 1 year total shareholder return remains positive. This suggests recent weakness contrasts with a stronger longer term outcome as investors weigh new launches like Elyra and portfolio changes.

If Elyra has you thinking about how medical technology could shape your portfolio, it may be worth scanning a wider set of healthcare-focused opportunities through 39 healthcare AI stocks.

With the stock down over the past 3 and 5 years but still showing a 1 year total return of 13.1%, and trading at roughly a 22% discount to one valuation estimate, is there a genuine opportunity here, or is future growth already priced in?

Most Popular Narrative: 23.5% Undervalued

With Becton Dickinson last closing at $147.12 against a narrative fair value of $192.31, the current price sits well below what this widely followed view considers reasonable, and that gap is anchored in detailed assumptions about product launches, margins, and capital returns.

The pending separation of the Biosciences and Diagnostic Solutions business will transform BD into a pure-play medical technology leader with a consumables-heavy portfolio (>90% of revenue), enabling higher cash flow predictability and margin improvement, while anticipated aggressive share buybacks directly support EPS growth.

Curious what earnings path, revenue mix shift, and margin profile underpin that valuation gap and future P/E assumption? The narrative spells out a detailed roadmap, including how analysts think buybacks and a more consumables driven portfolio could reshape Becton Dickinson's financial profile over time.

Result: Fair Value of $192.31 (UNDERVALUED)

However, this optimistic setup still faces real questions related to tariff pressures, including the expected US$275m impact in fiscal 2026, as well as execution risk on the planned business separation.

Next Steps

If this mix of potential upside and real risks feels finely balanced, do not wait to check the details yourself. Review the 5 key rewards and 2 important warning signs

Looking for more investment ideas?

Once you are done reviewing Becton Dickinson, take a moment to scan a few broader stock lists that could reveal opportunities you have not considered yet.

• Target stability first by checking companies in the 64 resilient stocks with low risk scores that score well on resilience and downside protection.
• Hunt for value by reviewing the 46 high quality undervalued stocks, which highlights stocks combining quality fundamentals with prices that may sit below some estimates of fair worth.
• Spot potential future standouts using the screener containing 22 high quality undiscovered gems, focusing on underfollowed stocks with financials that some investors might be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.